Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
Silence brings the noise to Takeda with phase 2 blood cancer win
A phase 2 trial of Silence’s divesiran hit its primary endpoint, emboldening the biotech to advance a potential challenger to Takeda’s rusfertide.
Nick Paul Taylor
Aug 10, 2026 7:31am
AstraZeneca pays CSPC $30M to form kidney drug discovery pact
Jul 3, 2026 8:00am
Novartis dystrophy data tee up regulatory talks on Avidity drug
Jun 12, 2026 4:30am
Alnylam pays Inceptive $30M to transform siRNA design
Jun 4, 2026 4:13am
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
Apr 29, 2026 8:38am
The 'diabolical' molecule set to become biotech's next gold rush
Apr 9, 2026 8:00am
